ABSCF:OTC-AB Science S.A (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | OTC

Last Closing Price

USD 15.40

Change

-0.16 (-1.03)%

Market Cap

USD 0.72B

Volume

280.00

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

AB Science S.A., a clinical-stage pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines. Its lead compound is the masitinib, a tyrosine kinase inhibitor that is in Phase III clinical trials for the treatment of prostate and pancreatic cancer, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's, severe asthma, and mastocytosis diseases. The company is also developing AB8939, synthetic microtubule destabilizer for the treatment of acute myeloid leukemia; and AB20001, which is in Phase II clinical trial to evaluate the safety and efficacy of masitinib combined with isoquercetin in hospitalized patients with moderate and severe COVID-19. The company markets its masitinib under the Masivet brand in Europe. AB Science S.A. was founded in 2001 and is headquartered in Paris, France.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-10-27 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MKGAF MERCK Kommanditgesellschaft au..

-2.67 (-1.13%)

USD102.33B 32.30 20.03
MKKGY MERCK Kommanditgesellschaft au..

-0.09 (-0.19%)

USD102.28B 32.21 20.03
TKPHF Takeda Pharmaceutical Company ..

+0.41 (+1.48%)

USD43.55B 11.50 0.07
ESALY Eisai Co. Ltd

+0.07 (+0.09%)

USD20.40B 38.75 0.17
ESALF Eisai Co. Ltd

N/A

USD20.12B 38.24 0.17
SGIOF Shionogi & Co. Ltd

-0.30 (-0.46%)

USD19.87B 18.70 0.11
SGIOY Shionogi & Co. Ltd

-0.10 (-0.61%)

USD19.70B 18.55 0.11
SFOSF Shanghai Fosun Pharmaceutical ..

-0.35 (-7.06%)

USD19.40B 18.67 2.49
TEVJF Teva Pharmaceutical Industries..

N/A

USD11.31B 900.00 16.02
MTZPY Mitsubishi Tanabe Pharma Corpo..

N/A

USD10.43B 79.00 0.21

ETFs Containing ABSCF

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -34.44% 36% F 20% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -34.44% 36% F 19% F
Trailing 12 Months  
Capital Gain 27.17% 60% D- 52% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 27.17% 59% F 50% F
Trailing 5 Years  
Capital Gain 26.54% 61% D- 56% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 26.54% 61% D- 54% F
Average Annual (5 Year Horizon)  
Capital Gain 30.21% 57% F 64% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 30.21% 56% F 63% D
Risk Return Profile  
Volatility (Standard Deviation) 84.34% 54% F 36% F
Risk Adjusted Return 35.82% 69% D+ 57% F
Market Capitalization 0.72B 85% B 64% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio N/A N/A N/A N/A N/A
Price / Cash Flow Ratio -53.64 90% A- 91% A-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital 142.83% 93% A 95% A
Return on Assets -33.98% 32% F 19% F
Debt to Equity Ratio -56.96% 85% B 93% A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.87 53% F 50% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector